These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 24150871)
1. Animal models of scleroderma: current state and recent development. Asano Y; Sato S Curr Rheumatol Rep; 2013 Dec; 15(12):382. PubMed ID: 24150871 [TBL] [Abstract][Full Text] [Related]
2. Recent advances in animal models of systemic sclerosis. Asano Y J Dermatol; 2016 Jan; 43(1):19-28. PubMed ID: 26782003 [TBL] [Abstract][Full Text] [Related]
4. [A Uuifying hypothesis for the pathogenesis of systemic sclerosis based on the deficiency of transcription factor Fli1 - the development of a new animal model of systemic sclerosis -]. Asano Y Nihon Rinsho Meneki Gakkai Kaishi; 2014; 37(6):475-87. PubMed ID: 25748132 [TBL] [Abstract][Full Text] [Related]
5. Double heterozygous mice for Klf5 and Fli1 genes: a new animal model of systemic sclerosis recapitulating its three cardinal pathological features. Asano Y Med Mol Morphol; 2015 Sep; 48(3):123-8. PubMed ID: 25986681 [TBL] [Abstract][Full Text] [Related]
6. Epigenetic suppression of Fli1, a potential predisposing factor in the pathogenesis of systemic sclerosis. Asano Y Int J Biochem Cell Biol; 2015 Oct; 67():86-91. PubMed ID: 26055516 [TBL] [Abstract][Full Text] [Related]
7. Critical Appraisal of the Utility and Limitations of Animal Models of Scleroderma. Tsujino K; Sheppard D Curr Rheumatol Rep; 2016 Jan; 18(1):4. PubMed ID: 26711695 [TBL] [Abstract][Full Text] [Related]
8. Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis. Noda S; Asano Y; Nishimura S; Taniguchi T; Fujiu K; Manabe I; Nakamura K; Yamashita T; Saigusa R; Akamata K; Takahashi T; Ichimura Y; Toyama T; Tsuruta D; Trojanowska M; Nagai R; Sato S Nat Commun; 2014 Dec; 5():5797. PubMed ID: 25504335 [TBL] [Abstract][Full Text] [Related]
9. Fli1 Downregulation in Scleroderma Myeloid Cells Has Profibrotic and Proinflammatory Effects. Bujor AM; El Adili F; Parvez A; Marden G; Trojanowska M Front Immunol; 2020; 11():800. PubMed ID: 32508810 [TBL] [Abstract][Full Text] [Related]
10. A potential contribution of altered cathepsin L expression to the development of dermal fibrosis and vasculopathy in systemic sclerosis. Yamashita T; Asano Y; Taniguchi T; Nakamura K; Saigusa R; Takahashi T; Ichimura Y; Toyama T; Yoshizaki A; Miyagaki T; Sugaya M; Sato S Exp Dermatol; 2016 Apr; 25(4):287-92. PubMed ID: 26661692 [TBL] [Abstract][Full Text] [Related]